AstraZeneca’s Tagriss approved in USA
US FDA has approved TAGRISSO for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer.
Pharmaceuticals, Biotechnology and Life Sciences
US FDA has approved TAGRISSO for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer.
Roche’s Media Spokesperson, Dr. Ulrike Engels-Lange, said in an email sent to Pharmaceutical Daily that the site exits are expected to affect approximately 1,200 positions.
Swiss-based Roche plans to exit four manufacturing sites globally. Workforce reduction is imminent.
A research-based healthcare company, Roche, has bought Adheron Therapeutics
Roche’s new HbA1c testing solution, the cobas c 513 analyser, is now available for countries accepting the CE mark,
New clinical data and abstracts on Roche’s Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF) are being presented at the European Respiratory Society (ERS) congress in Amsterdam.